Why the study?
Does a higher dose of losartan (100 mg/day or higher) provide greater clinical benefits compared to 50 mg/day in patients with hypertension, heart failure, and renal diseases?
Does a higher dose of losartan (100 mg/day or higher) provide greater clinical benefits compared to 50 mg/day in patients with hypertension, heart failure, and renal diseases?
This review suggests that the commonly prescribed 50 mg dose of losartan may be suboptimal, advocating for 100 mg/day or higher to maximize clinical benefits in hypertension, heart failure, and renal disease.
Answers are grounded in this paper and cite their sources.
May support higher losartan dosing; leaves open confirmation by RCTs before practice change.
INTRODUCTION: Blockade of the renin-angiotensin system is one of the major therapeutic strategies in the management of patients with essential hypertension, congestive heart failure and diabetic as well as non-diabetic renal diseases. As the first angiotensin II receptor blocker (ARB) on the market, losartan belongs to the most frequently prescribed ARB. AREA COVERED: The present review examines the pharmacokinetics of losartan with a special discussion on the dose of losartan that should be used in clinical practice to obtain the maximal benefits of the drug. Readers are provided with arguments suggesting that the dose of 50 mg losartan is probably too low and that losartan should preferably be prescribed at the dose of 100 mg/day or higher. EXPERT OPINION: Losartan is an effective antagonist of angiotensin II AT(1) receptors which has been shown to provide important clinical benefits in patients with hypertension, congestive heart failure and renal diseases. Losartan should be prescribed at the dose of 100 mg/day and the use of higher doses should be reconsidered in future studies to improve its clinical efficacy.
No takes yet. Share an insight, caveat, or question.
Burnier et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: